201 related articles for article (PubMed ID: 23611637)
1. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.
Maldonado R
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1001-14. PubMed ID: 23611637
[TBL] [Abstract][Full Text] [Related]
2. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
[TBL] [Abstract][Full Text] [Related]
4. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
Marcus SC; Wan GJ; Kemner JE; Olfson M
Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
[TBL] [Abstract][Full Text] [Related]
5. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.
Coghill D; Banaschewski T; Zuddas A; Pelaz A; Gagliano A; Doepfner M
BMC Psychiatry; 2013 Sep; 13():237. PubMed ID: 24074240
[TBL] [Abstract][Full Text] [Related]
6. [Benefit of the extended-release methylphenidate formulations: a comparative study in childhood].
Favreau A; Deseille-Turlotte G; Brault F; Giraudeau B; Krier C; Barthez MA; Castelnau P
Arch Pediatr; 2006 May; 13(5):442-8. PubMed ID: 16597499
[TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
[TBL] [Abstract][Full Text] [Related]
8. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
[TBL] [Abstract][Full Text] [Related]
9. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
Pierce D; Katic A; Buckwalter M; Webster K
J Clin Psychopharmacol; 2010 Oct; 30(5):554-64. PubMed ID: 20814325
[TBL] [Abstract][Full Text] [Related]
10. Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder.
Gormez V; Avery B; Mann H
Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2345-9. PubMed ID: 24065228
[TBL] [Abstract][Full Text] [Related]
11. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
Childress AC; Sallee FR; Berry SA
Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
[TBL] [Abstract][Full Text] [Related]
12. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
13. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.
Patrick KS; González MA; Straughn AB; Markowitz JS
Expert Opin Drug Deliv; 2005 Jan; 2(1):121-43. PubMed ID: 16296740
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.
Marchetti A; Magar R; Lau H; Murphy EL; Jensen PS; Conners CK; Findling R; Wineburg E; Carotenuto I; Einarson TR; Iskedjian M
Clin Ther; 2001 Nov; 23(11):1904-21. PubMed ID: 11768842
[TBL] [Abstract][Full Text] [Related]
15. [Clinical use of 30:70 controlled-release methylphenidate in the treatment of attention deficit hyperactivity disorder].
Mardomingo-Sanz MJ
Rev Neurol; 2012 Sep; 55(6):359-69. PubMed ID: 22972578
[TBL] [Abstract][Full Text] [Related]
16. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
17. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB
Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519
[TBL] [Abstract][Full Text] [Related]
18. [Does a morning dose of Methylphenidate Retard reduce hyperkinetic symptoms in the afternoon?].
Sinzig JK; Döpfner M; Plück J; Banaschewski T; Stephani U; Lehmkuhl G; Rothenberger A;
Z Kinder Jugendpsychiatr Psychother; 2004 Nov; 32(4):225-33. PubMed ID: 15565893
[TBL] [Abstract][Full Text] [Related]
19. A non-interventional study of extended-release methylphenidate in the routine treatment of adolescents with ADHD: effectiveness, safety and adherence to treatment.
Sobanski E; Döpfner M; Ose C; Fischer R
Atten Defic Hyperact Disord; 2013 Dec; 5(4):387-95. PubMed ID: 23794192
[TBL] [Abstract][Full Text] [Related]
20. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
